Chinese trial tests World's first major COVID-19 vaccine
NCT ID NCT04649021
Summary
This study tested the safety and immune response of the Pfizer-BioNTech COVID-19 vaccine in 960 healthy Chinese adults. Participants received either two doses of the vaccine or a placebo shot, with researchers tracking their antibody levels and any side effects for about a year. The goal was to see if the vaccine produced a strong immune response against COVID-19 and was well-tolerated in this population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Provincial Center for Disease Control and Prevention
Nanjing, 210009, China
Conditions
Explore the condition pages connected to this study.